Skip to Main Content
Table 1—

Pain visual analogue scale (UCS, UCES, and pooled cohorts)

PlaceboALC 500 mg t.i.d.ALC 1,000 mg t.i.d.ANOVA P value (placebo vs. 500 mg ALC)ANOVA P value (placebo vs. 1,000 mg ALC)
UCS      
    n 48 61 70   
    Baseline 50.40 ± 21.88 57.80 ± 25.92 59.94 ± 24.12 NS NS 
    Week 26 change −10.25 ± 29.45 −17.59 ± 32.53 −23.26 ± 26.33 NS 0.021 
    Week 52 change −9.72 ± 31.12 −13.16 ± 32.64 −25.53 ± 28.75 NS 0.024* 
UCES      
    n 61 43 58   
    Baseline 53.21 ± 25.96 48.28 ± 23.30 56.89 ± 26.94 NS NS 
    Week 26 change −18.93 ± 26.20 −14.21 ± 26.82 −21.92 ± 31.28 NS NS 
    Week 52 change −14.51 ± 27.49 −11.84 ± 30.80 −21.75 ± 34.58 NS NS 
Pooled cohorts      
    n 109 104 128   
    Baseline 51.98 ± 24.18 53.86 ± 25.20 58.56 ± 25.38 NS NS 
    Week 26 change −15.11 ± 27.89 −16.19 ± 30.21 −22.89 ± 28.57 NS 0.031 
    Week 52 change −12.40 ± 29.11 −12.61 ± 31.74 −23.82 ± 31.45 NS 0.025 
PlaceboALC 500 mg t.i.d.ALC 1,000 mg t.i.d.ANOVA P value (placebo vs. 500 mg ALC)ANOVA P value (placebo vs. 1,000 mg ALC)
UCS      
    n 48 61 70   
    Baseline 50.40 ± 21.88 57.80 ± 25.92 59.94 ± 24.12 NS NS 
    Week 26 change −10.25 ± 29.45 −17.59 ± 32.53 −23.26 ± 26.33 NS 0.021 
    Week 52 change −9.72 ± 31.12 −13.16 ± 32.64 −25.53 ± 28.75 NS 0.024* 
UCES      
    n 61 43 58   
    Baseline 53.21 ± 25.96 48.28 ± 23.30 56.89 ± 26.94 NS NS 
    Week 26 change −18.93 ± 26.20 −14.21 ± 26.82 −21.92 ± 31.28 NS NS 
    Week 52 change −14.51 ± 27.49 −11.84 ± 30.80 −21.75 ± 34.58 NS NS 
Pooled cohorts      
    n 109 104 128   
    Baseline 51.98 ± 24.18 53.86 ± 25.20 58.56 ± 25.38 NS NS 
    Week 26 change −15.11 ± 27.89 −16.19 ± 30.21 −22.89 ± 28.57 NS 0.031 
    Week 52 change −12.40 ± 29.11 −12.61 ± 31.74 −23.82 ± 31.45 NS 0.025 

Data are means ± SD for the change over baseline in intention-to-treat patients.

*

Repeated-measures ANOVA overall P value = 0.031.

Repeated-measures ANOVA overall P value = 0.017.

Close Modal

or Create an Account

Close Modal
Close Modal